Literature DB >> 11251168

Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.

B Chen1, I Zupkó, P A de Witte.   

Abstract

Hypericin, a polycyclic quinone obtained from plants of the Hypericum genus, exhibits strong photodynamic antitumor effects. In the present study, PDT efficacy of hypericin under different conditions was compared in a P388 mouse tumor model. Plasma and tumor drug measurements and assessment of vascular damage by fluorescein dye exclusion were performed to determine the relative contributions of vascular effects and direct tumor cytotoxicity. Furthermore, the influence of modifying tumor oxygenation on PDT effect was also evaluated. Study of PDT efficacy and tissue distribution revealed that PDT efficacy was more dependent on plasma concentration than tumor drug level. Fluorescein dye exclusion indicated the complete microvascular occlusion in the tumor and surrounding skin immediately after effective PDT treatments, while only a limited vascular occulation was observed after non-effective PDT treatment. It was found that neither tumor hypoxia induced by hydralazine nor increasing tumor oxygenation achieved by nicotinamide could significantly affect the effectiveness of various PDT protocols. These results suggest that tumor vasculature damage might be the primary mechanism of hypericin-mediated PDT effect. The existence of this potent secondary vascular effect is likely to account for the inability of tumor oxygenation modifiers to affect tumor response after PDT with hypericin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251168

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  An overview on development and application of an experimental platform for quantitative cardiac imaging research in rabbit models of myocardial infarction.

Authors:  Yuanbo Feng; Jan Bogaert; Raymond Oyen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.

Authors:  Zheng Huang; Qun Chen; Nadira Trncic; Susan M LaRue; Pierre-Hervé Brun; Brian C Wilson; Howard Shapiro; Fred W Hetzel
Journal:  Radiat Res       Date:  2004-06       Impact factor: 2.841

3.  First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.

Authors:  Yicheng Ni; Dieter Huyghe; Kristin Verbeke; Peter A de Witte; Johan Nuyts; Luc Mortelmans; Feng Chen; Guy Marchal; Alfons M Verbruggen; Guy M Bormans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

4.  Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.

Authors:  Junjie Li; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  J Cancer       Date:  2013-01-22       Impact factor: 4.207

5.  Early assessment of tumor response to photodynamic therapy using combined diffuse optical and diffuse correlation spectroscopy to predict treatment outcome.

Authors:  Patricia S P Thong; Kijoon Lee; Hui-Jin Toh; Jing Dong; Chuan-Sia Tee; Kar-Perng Low; Pui-Haan Chang; Ramaswamy Bhuvaneswari; Ngian-Chye Tan; Khee-Chee Soo
Journal:  Oncotarget       Date:  2017-03-21

6.  Novel Insights into the Effect of Hyperforin and Photodynamic Therapy with Hypericin on Chosen Angiogenic Factors in Colorectal Micro-Tumors Created on Chorioallantoic Membrane.

Authors:  Martin Majerník; Rastislav Jendželovský; Marián Babinčák; Ján Košuth; Juraj Ševc; Zuzana Tonelli Gombalová; Zuzana Jendželovská; Monika Buríková; Peter Fedoročko
Journal:  Int J Mol Sci       Date:  2019-06-19       Impact factor: 5.923

Review 7.  Antiproliferative Effects of St. John's Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies.

Authors:  Alessandro Allegra; Alessandro Tonacci; Elvira Ventura Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2020-12-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.